{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:48:42Z","timestamp":1783748922619,"version":"3.55.0"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Clozapine, a second-generation antipsychotic (SGA), is considered the gold standard medication to treat patients with treatment-resistant schizophrenia (TRS). Despite its efficacy, clozapine is associated with adverse effects, notably neutropenia and agranulocytosis. Other hematological adverse effects are less common. Severe anemia is a rare adverse effect seldom reported in the literature and is typically associated with pure red cell aplasia (PRCA). Nevertheless, the benefits of clozapine in managing TRS make rechallenge a reasonable option.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case Report<\/jats:title>\n                  <jats:p>We present the case of a 35-year-old man with TRS, resistant to previous antipsychotics, who experienced severe anemia during clozapine treatment. An investigation for clozapine-induced anemia revealed PRCA on myelogram. After discontinuing clozapine, the patient\u2019s hemoglobin levels recovered. Subsequent treatments with olanzapine, zuclopenthixol, and aripiprazole proved ineffective, leading us to consider a clozapine rechallenge. The rechallenge, monitored for 58 days, resulted in improved psychiatric symptoms and stable hemoglobin levels. The patient remained stable during 6 months of follow-up, with no hematological changes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>PRCA is a very rare adverse effect of clozapine. The cause of drug-induced PRCA is still unknown; for clozapine, there are no studies. Rechallenge after a severe and rare adverse effect is a complex decision. This case is the first to report a successful clozapine rechallenge following severe anemia without other blood dyscrasias, emphasizing the imperative need for close monitoring during the rechallenge process. Further study is warranted to understand the predictive factors for a successful outcome in clozapine rechallenges.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/schbul\/sbae028","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T20:20:43Z","timestamp":1710879643000},"page":"717-719","source":"Crossref","is-referenced-by-count":3,"title":["Successful Clozapine Rechallenge After Clozapine-Induced Severe Anemia: A Case Report"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5445-8899","authenticated-orcid":false,"given":"Felipe Mendon\u00e7a Rocha","family":"Barros","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Universidade Estadual de Campinas (UNICAMP) , Campinas , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur Cardoso","family":"Tolentino","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Universidade Estadual de Campinas (UNICAMP) , Campinas , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lais Soares Ker","family":"Marques","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Universidade Estadual de Campinas (UNICAMP) , Campinas , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro Xavier de Camargo","family":"Schlittler","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Universidade Estadual de Campinas (UNICAMP) , Campinas , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina Diniz","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Universidade Estadual de Campinas (UNICAMP) , Campinas , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Dalgalarrondo","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Universidade Estadual de Campinas (UNICAMP) , Campinas , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Luchesi","family":"Barnes","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Universidade Estadual de Campinas (UNICAMP) , Campinas , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amilton","family":"dos Santos Junior","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Universidade Estadual de Campinas (UNICAMP) , Campinas , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio Eduardo Muller","family":"Banzato","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Universidade Estadual de Campinas (UNICAMP) , Campinas , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,19]]},"reference":[{"key":"2024043011193218700_CIT0001","first-page":"137","article-title":"Unique effects of clozapine: a pharmacological perspective","volume-title":"Advances in Pharmacology","author":"Khokhar","year":"2018"},{"issue":"2","key":"2024043011193218700_CIT0002","doi-asserted-by":"crossref","first-page":"18com12123","DOI":"10.4088\/JCP.18com12123","article-title":"Clinical guidance on the identification and management of treatment-resistant schizophrenia","volume":"80","author":"Kane","year":"2019","journal-title":"J Clin Psychiatry."},{"issue":"7","key":"2024043011193218700_CIT0003","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40263-022-00932-2","article-title":"A guideline and checklist for initiating and managing clozapine treatment in patients with treatment-resistant schizophrenia","volume":"36","author":"Correll","year":"2022","journal-title":"CNS Drugs"},{"issue":"2","key":"2024043011193218700_CIT0004","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1097\/MJT.0000000000000715","article-title":"Clozapine rechallenge after major adverse effects: clinical guidelines based on 259 cases","volume":"25","author":"Manu","year":"2018","journal-title":"Am J Ther."},{"issue":"2","key":"2024043011193218700_CIT0005","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4103\/ijp.IJP_686_17","article-title":"Clozapine-induced bicytopenia: an unusual side effect","volume":"50","author":"Faye","year":"2018","journal-title":"Indian J Pharmacol."},{"issue":"12","key":"2024043011193218700_CIT0006","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.4088\/JCP.14m09143","article-title":"Clozapine and anemia: a 2-year follow-up study","volume":"76","author":"Lee","year":"2015","journal-title":"J Clin Psychiatry."},{"key":"2024043011193218700_CIT0007","doi-asserted-by":"crossref","first-page":"103619","DOI":"10.1016\/j.ajp.2023.103619","article-title":"Recurrence of clozapine associated bicytopenia (Leucopenia and Anaemia) while rechallenge: a case report","volume":"85","author":"Yadav","year":"2023","journal-title":"Asian J Psychiatr."},{"issue":"05","key":"2024043011193218700_CIT0008","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5414\/CP203679","article-title":"Clozapine-induced anemia: a case-report","volume":"58","author":"Eleftheriou","year":"2020","journal-title":"Int J Clin Pharmacol Ther."},{"issue":"6","key":"2024043011193218700_CIT0009","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/JCP.0000000000000227","article-title":"Clozapine administration and the risk of drug-related pure red cell aplasia: a novel case report","volume":"34","author":"Kikuchi","year":"2014","journal-title":"J Clin Psychopharmacol."},{"issue":"5","key":"2024043011193218700_CIT0010","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/070674370304800519","article-title":"Clozapine-induced aplastic anemia in a patient with Parkinson\u2019s disease","volume":"48","author":"Ziegenbein","year":"2003","journal-title":"Can J Psychiatry."},{"issue":"5","key":"2024043011193218700_CIT0011","doi-asserted-by":"crossref","first-page":"38","DOI":"10.7453\/gahmj.2013.008","article-title":"The CARE guidelines: consensus-based clinical case reporting guideline development","volume":"2","author":"Gagnier","year":"2013","journal-title":"Glob Adv Health Med"},{"key":"2024043011193218700_CIT0012","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.psychres.2017.06.068","article-title":"Clozapine versus other antipsychotics during the first 18 weeks of treatment: a retrospective study on risk factor increase of blood dyscrasias","volume":"256","author":"Fabrazzo","year":"2017","journal-title":"Psychiatry Res."},{"key":"2024043011193218700_CIT0013","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12888-020-02592-2","article-title":"Clozapine rechallenge and initiation despite neutropenia - a practical, step-by-step guide","volume":"20","author":"Silva","year":"2020","journal-title":"BMC Psychiatry"},{"issue":"4","key":"2024043011193218700_CIT0014","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/j.1365-2141.2000.02429.x","article-title":"Pure red cell aplasia","volume":"111","author":"Fisch","year":"2000","journal-title":"Br J Haematol."}],"container-title":["Schizophrenia Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/50\/3\/717\/57360408\/sbae028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/50\/3\/717\/57360408\/sbae028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T11:19:48Z","timestamp":1714475988000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article\/50\/3\/717\/7632070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,19]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,19]]},"published-print":{"date-parts":[[2024,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/schbul\/sbae028","relation":{},"ISSN":["0586-7614","1745-1701"],"issn-type":[{"value":"0586-7614","type":"print"},{"value":"1745-1701","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,1]]},"published":{"date-parts":[[2024,3,19]]}}}